Literature DB >> 19088280

Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro.

Jason L Starkey1, Estelle F Chiari, Harriet C Isom.   

Abstract

Hepatitis B virus (HBV) covalently closed circular (CCC) DNA is the source of HBV transcripts and persistence in chronically infected patients. The novel aspect of this study was to determine the effect of RNA interference (RNAi) on HBV CCC DNA when administered prior to establishment of HBV replication or during chronic HBV infection. HBV replication was initiated in HepG2 cells by transduction with HBV baculovirus. Subculture of HBV-expressing HepG2 cells at 10 days post-transduction generates a system in which HBV replication is ongoing and HBV is expressed largely from CCC DNA, thus simulating chronic HBV infection. HepG2 cells were transduced with short hairpin RNA (shRNA)-expressing baculovirus prior to initiation of HBV replication or during chronic HBV replication, and the levels of HBV RNA, HBV surface antigens (HBsAg) and replicative intermediates (RI), extracellular (EC) and CCC DNA species were measured. HBsAg, HBV RNA and DNA levels were markedly reduced until day 8 whether cells were transduced with shRNA prior to or during a chronic infection; however, the CCC DNA species were only affected when shRNA was administered prior to initiation of infection. We conclude that RNAi may have a therapeutic value for controlling HBV replication at the level of RI and EC DNA and for reducing establishment of CCC DNA during HBV infection. Our data support previous findings demonstrating the stability of HBV CCC DNA following antiviral therapy. This study also reports the development of a novel HBV baculovirus subculture system that can be used to evaluate antiviral effects on chronic HBV replication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19088280      PMCID: PMC2659548          DOI: 10.1099/vir.0.004408-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  46 in total

1.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Hepatitis B virus infection.

Authors:  H S Margolis
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 3.  Recombinant baculoviruses as mammalian cell gene-delivery vectors.

Authors:  Thomas A Kost; J Patrick Condreay
Journal:  Trends Biotechnol       Date:  2002-04       Impact factor: 19.536

4.  Therapeutic inhibition of hepatitis B virus surface antigen expression by RNA interference.

Authors:  Tsung-Lin Cheng; Wen-Wei Chang; Ih-Jen Su; Ming-Derg Lai; Wenya Huang; Huan-Yao Lei; Wen-Tsan Chang
Journal:  Biochem Biophys Res Commun       Date:  2005-10-28       Impact factor: 3.575

5.  RNA interference mediated in human primary cells via recombinant baculoviral vectors.

Authors:  Linda J Nicholson; Marie Philippe; Alan J Paine; Derek A Mann; Colin T Dolphin
Journal:  Mol Ther       Date:  2005-04       Impact factor: 11.454

6.  Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.

Authors:  Susan L Uprichard; Bryan Boyd; Alana Althage; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-07       Impact factor: 11.205

7.  Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors.

Authors:  Michael D Moore; Michael J McGarvey; Rebecca A Russell; Bryan R Cullen; Myra O McClure
Journal:  J Gene Med       Date:  2005-07       Impact factor: 4.565

8.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.

Authors:  J S Markowitz; P Martin; A J Conrad; J F Markmann; P Seu; H Yersiz; J A Goss; P Schmidt; A Pakrasi; L Artinian; N G Murray; D K Imagawa; C Holt; L I Goldstein; R Stribling; R W Busuttil
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

Review 9.  Baculovirus as versatile vectors for protein expression in insect and mammalian cells.

Authors:  Thomas A Kost; J Patrick Condreay; Donald L Jarvis
Journal:  Nat Biotechnol       Date:  2005-05       Impact factor: 54.908

10.  RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant.

Authors:  Hui-Lin Wu; Li-Rung Huang; Chuan-Chuan Huang; Hsiao-Lei Lai; Chun-Jen Liu; Yu-Tzu Huang; Yun-Wei Hsu; Cheng-Yi Lu; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

View more
  10 in total

Review 1.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

2.  Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs.

Authors:  Justin Hean; Carol Crowther; Abdullah Ely; Rafique Ul Islam; Samantha Barichievy; Kristie Bloom; Marc S Weinberg; Willem Al van Otterlo; Charles B de Koning; Felix Salazar; Patricia Marion; Eric B Roesch; Marc Lemaitre; Piet Herdewijn; Patrick Arbuthnot
Journal:  Artif DNA PNA XNA       Date:  2010-07

3.  Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.

Authors:  Marc S Weinberg; Patrick Arbuthnot
Journal:  Genome Med       Date:  2010-04-28       Impact factor: 11.117

4.  trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.

Authors:  Richard A Heipertz; Jason L Starkey; Thomas G Miller; Jianming Hu; Harriet C Isom
Journal:  Virology       Date:  2009-04-19       Impact factor: 3.616

5.  Identification of an effective siRNA target site and functional regulatory elements, within the hepatitis B virus posttranscriptional regulatory element.

Authors:  Nattanan Panjaworayan; Sunchai Payungporn; Yong Poovorawan; Chris M Brown
Journal:  Virol J       Date:  2010-09-08       Impact factor: 4.099

Review 6.  Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications.

Authors:  Chi-Yuan Chen; Chin-Yu Lin; Guan-Yu Chen; Yu-Chen Hu
Journal:  Biotechnol Adv       Date:  2011-04-28       Impact factor: 14.227

Review 7.  Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?

Authors:  Ganesh Selvaraj Duraisamy; Dattatry Bhosale; Ivana Lipenská; Ivana Huvarova; Daniel Růžek; Marc P Windisch; Andrew D Miller
Journal:  Viruses       Date:  2020-09-07       Impact factor: 5.048

Review 8.  Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2022-09-16       Impact factor: 5.818

9.  Changes in innate and permissive immune responses after hbv transgenic mouse vaccination and long-term-siRNA treatment [corrected].

Authors:  Guang-Li Ren; Guang-Yu Huang; Hong Zheng; Ying Fang; Heng-Hao Ma; Man-Chun Xu; Hong-Bin Zhang; Wei-Yun Zhang; Ya-Gang Zhao; Da-Yong Sun; Wen-Kui Hu; Jian Liu
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

Review 10.  Baculovirus-mediated gene delivery and RNAi applications.

Authors:  Kaisa-Emilia Makkonen; Kari Airenne; Seppo Ylä-Herttulala
Journal:  Viruses       Date:  2015-04-22       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.